Search for: "BIOGEN INC."
Results 61 - 80
of 259
Sorted by Relevance
|
Sort by Date
17 Aug 2010, 9:52 pm
Biogen Idec, and Association for Molecular Pathology v. [read post]
2 Aug 2017, 9:59 pm
Biogen Inc. et al. [read post]
19 Dec 2008, 9:20 pm
Biogen IDEC. [read post]
2 Aug 2022, 10:00 pm
Biogen Inc., a global biotechnology company, denies that it violated the federal Anti-Kickback Statute and False Claims Act by paying healthcare professionals for fraudulent speaking engagements in order to incentivize them to prescribe the company’s drugs, among other allegations stemming from a whistleblower suit. [read post]
2 Aug 2022, 10:00 pm
Biogen Inc., a global biotechnology company, denies that it violated the federal Anti-Kickback Statute and False Claims Act by paying healthcare professionals for fraudulent speaking engagements in order to incentivize them to prescribe the company’s drugs, among other allegations stemming from a whistleblower suit. [read post]
23 Feb 2021, 3:31 pm
Biogen, Inc., that restraints in contracts between businesses should be evaluated using the same “rule of reason” standard that courts use to analyze antitrust violations under the Cartwright Act. [read post]
2 Aug 2022, 10:00 pm
Biogen Inc., a global biotechnology company, denies that it violated the federal Anti-Kickback Statute and False Claims Act by paying healthcare professionals for fraudulent speaking engagements in order to incentivize them to prescribe the company’s drugs, among other allegations stemming from a whistleblower suit. [read post]
2 Aug 2022, 10:00 pm
Biogen Inc., a global biotechnology company, denies that it violated the federal Anti-Kickback Statute and False Claims Act by paying healthcare professionals for fraudulent speaking engagements in order to incentivize them to prescribe the company’s drugs, among other allegations stemming from a whistleblower suit. [read post]
2 Aug 2022, 10:00 pm
Biogen Inc., a global biotechnology company, denies that it violated the federal Anti-Kickback Statute and False Claims Act by paying healthcare professionals for fraudulent speaking engagements in order to incentivize them to prescribe the company’s drugs, among other allegations stemming from a whistleblower suit. [read post]
2 Aug 2022, 10:00 pm
Biogen Inc., a global biotechnology company, denies that it violated the federal Anti-Kickback Statute and False Claims Act by paying healthcare professionals for fraudulent speaking engagements in order to incentivize them to prescribe the company’s drugs, among other allegations stemming from a whistleblower suit. [read post]
28 Sep 2020, 8:00 am
by Dennis Crouch Biogen MA, Inc. v. [read post]
24 Jun 2009, 9:41 am
One that falls in the dangerous category is Tysabri, manufactured by Biogen, Inc. [read post]
10 Aug 2022, 12:00 pm
Biogen Idec, Inc., Civ. [read post]
28 May 2009, 9:59 pm
Johnson, Bryan Cave; Scott Gottlieb M.D., a senior fellow at the American Enterprise Institute; Vaughn Kailian, MPM Capital LLP; and David Pyott, Chairman and CEO of Allergan, Inc. [read post]
19 Aug 2010, 3:01 pm
In a deal spotlighting the value that can be created when a strong research team implements a strategic intellectual property protection plan, Pittsburgh-based Knopp Neurosciences, Inc. recently signed an agreement worth $80 million in which Knopp and Biogen, Inc. will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. [read post]
22 Dec 2008, 11:28 pm
By Kevin E. [read post]
18 Aug 2020, 11:30 am
Biogen, Inc. [read post]
25 Jun 2013, 9:52 pm
In Classen Immunotherapies, Inc. v. [read post]
3 Dec 2021, 2:39 pm
Biogen MA Inc. [read post]
13 Nov 2019, 9:15 am
Biogen, Inc., IPR2016-01614, Paper 65 (Feb. 21, 2018), the Petitioners relied on a copyrighted label for Rituxan that was published on the internet and available on the Food and Drug Administration’s (FDA’s) and on Biogen’s website all before the critical date. [read post]
